Ke-Da相关文献与解析，生知库 | 链接生命科学的每一步

Logarithmically transformed lactate-to-hemoglobin ratio demonstrates a threshold effect on 28-day mortality in sepsis: Analysis of the MIMIC-IV database

对数转换后的乳酸/血红蛋白比值对脓毒症患者28天死亡率存在阈值效应：MIMIC-IV数据库分析

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0342994

Chen, Huang; Ke, Da; Zheng, Xiuqin; Song, Haiyang; Lin, Shirong

Breast cancer: pathogenesis and treatments

乳腺癌：发病机制和治疗

期刊:Signal Transduction and Targeted Therapy

影响因子:52.7

doi:10.1038/s41392-024-02108-4

Xiong, Xin; Zheng, Le-Wei; Ding, Yu; Chen, Yu-Fei; Cai, Yu-Wen; Wang, Lei-Ping; Huang, Liang; Liu, Cui-Cui; Shao, Zhi-Ming; Yu, Ke-Da

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

卡铂强化辅助化疗与标准化疗对高危早期三阴性乳腺癌女性患者生存率的影响（CITRINE）：一项随机、开放标签的3期临床试验

期刊:Bmj-British Medical Journal

影响因子:42.7

doi:10.1136/bmj-2025-085457

Liu, Yin; Gong, Yue; Zhu, Xiu-Zhi; Liu, Guang-Yu; Yu, Ke-Da; Yang, Fan; Chen, Li; He, Min; Hu, Zhen; Chen, Can-Ming; Cao, A-Yong; Li, Jun-Jie; Hou, Yi-Feng; Di, Gen-Hong; Wu, Jiong; Jiang, Yi-Zhou; Fan, Lei; Wang, Zhong-Hua; Shao, Zhi-Ming

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Sitravatinib 联合 tislelizumab 治疗局部复发或转移性三阴性乳腺癌：一项多队列、单臂 II 期临床试验（SPARK 试验）

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-025-02505-5

Liu, Xi-Yu; Sui, Xin-Yi; Xu, Ying; Yang, Fan; Wu, Song-Yang; Zhu, Xiu-Zhi; Zuo, Ke; Cao, Shuo-Wen; Jin, Xi; Chen, Li; Ma, Lin-Xiaoxi; Zhang, Wen-Juan; Ye, Fu-Gui; Qu, Fei-Lin; Ma, Ding; Xiao, Yi; Di, Gen-Hong; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Hu, Xin; Jiang, Yi-Zhou; Wang, Zhong-Hua; Shao, Zhi-Ming; Fan, Lei

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study

一项基于化疗敏感性的前瞻性 II 期新辅助治疗研究——FINEST 研究（HR+/HER2- 乳腺癌）。

期刊:Cancer Communications

影响因子:24.9

doi:10.1002/cac2.12649

Chen, Li; Wu, Wen-Ya; Liang, Fei; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Di, Gen-Hong; Fan, Lei; Wang, Zhong-Hua; Li, Jun-Jie; Shao, Zhi-Ming

Size-dependent translocation of polystyrene nanoplastics across biological barriers in mammals

聚苯乙烯纳米塑料在哺乳动物体内跨越生物屏障的尺寸依赖性转运

期刊:Nature Communications

影响因子:15.7

doi:10.1038/s41467-025-67876-1

Zhang, Hong-Jie; Li, Sicheng; Wang, Xin-Lei; Zhang, Ke-Da; Fang, Hai-Tao; Wu, Xuan; Huang, Ziyun; Jiang, Wei; Yang, Liuyan; Tan, Qiao-Guo; Pan, Bingcai; Ji, Rong; Wang, Ping; Xing, Baoshan; Miao, Ai-Jun

发表日期：2025

文献求助收藏

RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond

肿瘤微环境中的RNA修饰：对癌症-免疫循环及其他方面的深入理解

期刊:Experimental Hematology & Oncology

影响因子:13.5

doi:10.1186/s40164-025-00648-1

Ding, You-Peng; Liu, Cui-Cui; Yu, Ke-Da

SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer.

SNX10 缺乏会通过改变 HER2 阳性乳腺癌中 HER2 的转运来降低对 HER2 抗体药物偶联物的敏感性

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.2417586122

Chen Yu-Fei, Zhang Qing-Hua, Zhang Zhong-Wei, Zhou Yu-Jie, Liu Cui-Cui, Shao Zhi-Ming, Yu Ke-Da

Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities

癌症基因组不稳定性的代谢驱动因素：机制和治疗机遇

Application of nanoparticles in the therapeutic management of endometrial cancer

纳米颗粒在子宫内膜癌治疗中的应用

Logarithmically transformed lactate-to-hemoglobin ratio demonstrates a threshold effect on 28-day mortality in sepsis: Analysis of the MIMIC-IV database

对数转换后的乳酸/血红蛋白比值对脓毒症患者28天死亡率存在阈值效应：MIMIC-IV数据库分析

Breast cancer: pathogenesis and treatments

乳腺癌：发病机制和治疗

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

卡铂强化辅助化疗与标准化疗对高危早期三阴性乳腺癌女性患者生存率的影响（CITRINE）：一项随机、开放标签的3期临床试验

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Sitravatinib 联合 tislelizumab 治疗局部复发或转移性三阴性乳腺癌：一项多队列、单臂 II 期临床试验（SPARK 试验）

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study

一项基于化疗敏感性的前瞻性 II 期新辅助治疗研究——FINEST 研究（HR+/HER2- 乳腺癌）。

Size-dependent translocation of polystyrene nanoplastics across biological barriers in mammals

聚苯乙烯纳米塑料在哺乳动物体内跨越生物屏障的尺寸依赖性转运

RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond

肿瘤微环境中的RNA修饰：对癌症-免疫循环及其他方面的深入理解

SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer.

SNX10 缺乏会通过改变 HER2 阳性乳腺癌中 HER2 的转运来降低对 HER2 抗体药物偶联物的敏感性